15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for RDY yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $11.74 current
Highest Target—
Average Target—
Lowest Target—
RDY analyst recommendation trends
86420
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Strong BuyBuyHoldSellStrong Sell
RATING
DEC
JAN
FEB
MAR
APR
MAY
Strong Buy
0
0
0
0
0
0
Buy
1
1
1
1
1
1
Hold
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of May, 1 of 1 firms rate RDY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RDY EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 4 analysts
Next period, 4 analysts expect Dr. Reddy’s Laboratories Ltd ADR to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $43.85, growing to $62.08 the year after.
REVENUE · NEXT QUARTER
$90.3B
Range $88.5B – $93.0B · 4 analysts · +3% YoY
Revenue is expected to reach $90.3B (range $88.5B – $93.0B), +3.4% year-over-year. Full-year consensus is $350.7B, rising to $394.1B next year.
Top analysts covering Dr. Reddy’s Laboratories Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RDY.
#1
Balaji Prasad
Barclays · Rank #147
Buy
$17.00+44.7% to target
Overall win rate
44%
+ Follow
#2
DK
Damayanti Kerai
HSBC
Buy
$16.90+43.9% to target
Coverage
—
+ Follow
RDY stock forecast FAQ
Who is the most accurate analyst covering RDY?+
Among analysts who currently cover RDY, Balaji Prasad of Barclays has the strongest overall Quantellect track record (Rank #147). Their current call is Buy with a $17.00 target.
What is Dr. Reddy’s Laboratories Ltd ADR's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 4 analysts. Full-year EPS is projected at $43.85, rising to $62.08 the following year.
How much revenue is Dr. Reddy’s Laboratories Ltd ADR expected to report next quarter?+
Consensus revenue is $90.3B (range $88.5B – $93.0B). Full-year revenue is projected at $350.7B, growing to $394.1B next year.
Have analysts been upgrading or downgrading RDY lately?+
As of May, 1 of 1 firms rate RDY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RDY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
